Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 13/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3400825 | 0.89 | CYP1A2 (0.54) | CACNA1GRAB9ANPC1SLC2A1THRB | |
| SCHEMBL3406018 | 0.89 | HSD17B10 (0.49) | CACNA1GRAB9ANPC1SLC2A1THRB | |
| SCHEMBL3402624 | 0.87 | CACNA1G (0.51) | CACNA1GRAB9ANPC1SLC2A1 | |
| SCHEMBL3401783 | 0.85 | CACNA1G (0.53) | CACNA1GRAB9ANPC1 | |
| SCHEMBL3399980 | 0.83 | RAB9A (0.49) | CACNA1GRAB9ANPC1SLC2A1THRB | |
| SCHEMBL3402499 | 0.83 | CYP1A2 (0.53) | CACNA1GRAB9ANPC1THRB | |
| SCHEMBL3399710 | 0.83 | THRB (0.54) | CACNA1GRAB9ANPC1SLC2A1THRB | |
| SCHEMBL3404359 | 0.83 | RAB9A (0.51) | CACNA1GRAB9ANPC1SLC2A1THRB | |
| SCHEMBL3401247 | 0.83 | PPARD (0.48) | CACNA1GRAB9ANPC1SLC2A1THRB | |
| SCHEMBL3399947 | 0.83 | CACNA1G (0.51) | CACNA1GRAB9ANPC1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100297035-A1 | Thiazole Amides, Imidazole Amides and Related Analogues | LIGAND PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
| WO-2006089076-A9 | THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES | NEUROGEN CORP (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297035-A1 | Thiazole Amides, Imidazole Amides and Related Analogues | HRH3, HRH4, HRH2 | CACNA1G 2431/4885RAB9A 2102/4885NPC1 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.